LB-100 and LB-102, Lixte Biotechnology’s Protein Phosphatase 2A Inhibitors, Sensitize BCR-ABL Leukemia Stem Cells to Targeted Therapy with Tyrosine Kinase Inhibitors
09. Februar 2018 09:45 ET
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, Feb. 09, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) noted that investigators at the Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver,...